Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
Press Highlights of FY22
During the 2022 fiscal year, there were 98 press mentions for PCI programs, startups and partners. Some of the most popular and widely circulated stories are included here.
Peroxitech raises $25M Series A
PCIV startup Peroxitech Inc. announced the successful completion of a $25M Series A financing for treatment of acute lung injury (ALI) into clinical development.
Penn Engineering Lab develops next-generation drug delivery technologies
Mike Mitchell's lab has numerous ongoing research partnerships to support new therapeutic solutions with commercial entities that were facilitated by PCI.
Carisma Therapeutics continues to thrive and expand
Penn and Carisma Therapeutics (Carisma) have strengthened the intellectual property portfolio covering this technology with the issuance of five additional patents in 2022.
Penn ICorps Graduate and President’s Innovation Prize Winner Strella Biotech Raises $8 Million in Series A Funding Round
Read about how this Philadelphia-based agricultural biotech startup received funding from Mark Cuban, Google Ventures, and others.
Penn Medicine Co-Investment Program continues to thrive
Fiscal year 2022 saw the Co-Investment Program help launch and fund 2 new companies ViTToria Biotherapeutics and Dispatch Bio, as well as participate in follow-on rounds for Linnaeus Therapeutics, Car
Penn Engineering Graduates Develop a Device to Reduce Ocean Microplastic Pollution
Read about how May graduates won the 2022 President's Sustainability Prize for their device that reduces microplastic pollution.
CAR-T startup Vittoria Biotherapeutics launches
Vittoria Biotherapeutics' mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies.
PCI highlights innovation in Penn Robotics during Philly Tech Week
From May 6 - 12, PCI participated in the 12th annual Philly Tech Week, a conference hosted by Technical.ly Philly, to showcase some of the city's best technology and innovation.
Abrax Japan licenses technology from Penn
Abrax Japan entered into an exclusive licensing agreement for certain Penn-owned inventions relating to the therapeutic effects of thymic stromal lymphopoietin (TSLP).